Denmark· DK-28104781210
Edarbi
A azilsartan medoxomil product containing azilsartan kamedoxomil, registered in Denmark by Takeda Pharma A/S. The same ATC class is registered in 10 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Azilsartan medoxomil is registered in 10 of 19 countries.
Countries holding a registration under ATC C09CA09 (azilsartan medoxomil), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 6 of them publish a price we can compare per daily dose
Azilsartan medoxomil · ATC C09CA09
10 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of azilsartan medoxomil costs, country by country.
Normalised to the WHO defined daily dose (40 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Azilsartan medoxomil · price per daily dose (40 mg)
USD · FX 28 Sept 2026
- CH Switzerland$1.47
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Azilsartan Kamedoxomil
- Manufacturer
- Takeda Pharma A/S
- Country
- Denmark (DK)
- ATC code
- C09CA09
- ATC class
- Azilsartan medoxomil
- Defined daily dose
- 40 mg, O
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28104781210
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
170 interactions on record for azilsartan medoxomil.
Graded by severity as the source publishes them — 7 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Azilsartan medoxomil · interactions on record
170 records
- 7 severe
- 118 moderate
Most severe, free to view
- Potassium chlorideA12BA01severe
- Potassium citrateA12BA02severe
- Potassium gluconateA12BA05severe
- Potassium chlorideB05XA01severe
45 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under C09CA09
Azilsartan medoxomil, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/244a1ecb-ea00-469e-be82-651aefbd0fec GET /v1/drugs/244a1ecb-ea00-469e-be82-651aefbd0fec?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "tabletter",
"source": "dkma",
"strength": "40 mg",
"auth_role": "MOD",
"dk_drugid": "28104781210",
"substance": "Azilsartan Kamedoxomil",
"auth_procedure": "Central",
"in_medicinpriser": false,
"registration_date_serial": "40886"
}See everything about azilsartan medoxomil.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.